Dendreon Company Profile (NASDAQ:DNDN)

Analyst Ratings

Consensus Ratings for Dendreon (NASDAQ:DNDN) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Dendreon (NASDAQ:DNDN)
Show:
DateFirmActionRatingPrice TargetActions
11/12/2014Roth CapitalUpgradeSell -> Neutral$0.15View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/3/2014Credit Suisse Group AGInitiated CoverageNeutral$1.50 -> $0.98View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/2/2014Citigroup Inc.Reiterated RatingSell$2.00 -> $1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/13/2014R. F. LaffertyDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2014Cowen and CompanyLower Price Target$2.55 -> $2.33View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2014Jefferies GroupLower Price TargetUnderperform$2.00 -> $1.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Dendreon (NASDAQ:DNDN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/10/2014Q3($0.10)($0.14)$78.72 million$73.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/20/2014($0.18)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.25)($0.10)$73.37 million$82.16 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.28)($0.24)$69.19 million$68.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2014Q413($0.37)($0.17)$73.59 million$74.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q313($0.42)($0.44)$76.60 million$68.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.42)($0.45)$75.61 million$73.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.47)($0.48)$80.15 million$67.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2013Q4 2012($0.56)($0.26)$82.88 million$85.49 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2012Q312($0.75)($0.33)$80.68 million$78.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2011($0.70)($0.77)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dendreon (NASDAQ:DNDN)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Dendreon (NASDAQ:DNDN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Dendreon (NASDAQ:DNDN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Dendreon (NASDAQ:DNDN)
DateHeadline
07/22/16 03:34 PMHow Did JNJ's Pharmaceutical Segment Fare in 2Q16? - Market Realist
07/21/16 09:07 PMHow Were Johnson & Johnson's 2Q16 Earnings Trending? - Market Realist
07/21/16 03:47 PMHow Did JNJ’s Pharmaceutical Segment Fare in 2Q16?
06/23/16 02:34 PMStocks Leading The Fight Against Cancer
04/26/16 11:11 PMJohnson & Johnson's 1Q16 Earnings: Consumer Segment - Market Realist - Johnson & Johnson's 1Q16 Earnings: Consumer SegmentMarket RealistZytiga competes with Dendreon's (DNDN) Provenge. Investors can ... The overall business of Johnson & Johnson (JNJ) is classified into three business segments: the pharmaceuticals segment, the consumer segment, and the medical devices segment.
04/26/16 04:35 AMA Segment-by-Segment Breakdown of JNJ's 1Q16 Earnings - Market Realist - A Segment-by-Segment Breakdown of JNJ's 1Q16 EarningsMarket RealistThe overall business of Johnson & Johnson (JNJ) is classified into three business segments: the pharmaceuticals segment, the consumer segment, and the medical devices segment. .... Zytiga competes with Dendreon's (DNDN) Provenge. Imbruvica, a drug ...
04/22/16 10:48 PMJohnson & Johnson's 1Q15 Earnings: Changes in Growth Rate - Market Realist - Market RealistJohnson & Johnson's 1Q15 Earnings: Changes in Growth RateMarket RealistZytiga competes with Dendreon's (DNDN) Provenge. Investors can consider ETFs such as the iShares US Pharmaceuticals ETF (IHE), which holds 9.3% of its total assets in Johnson & Johnson, or the Fidelity MSCI Healthcare Index ETF (FHLC), which holds ...and more »
04/22/16 05:42 PMJohnson & Johnson’s 1Q16: Other Pharmaceuticals Franchises - Zytiga’s revenue was nearly flat at $558 million in 1Q16 compared to 1Q15. Zytiga competes with Dendreon’s (DNDN) Provenge. Imbruvica, a drug used to treat chronic lymphocytic leukemia, reported a rise of over 100% in its revenue to $261 million ...
03/31/16 08:49 AMאימונותרפיה: לנצח את הסרטן ולהרוויח כסף תוך כדי, אך לא בקלות - Bizportal - אימונותרפיה: לנצח את הסרטן ולהרוויח כסף תוך כדי, אך לא בקלותBizportalמאז אישור ה-Keytruda אושרו כמה תרופות נוספות בתחום כמו ה- Provenge (תרופה שמתמרצת חיסון עצמי נגד סרטן הערמונית) של Dendreon (סימול: DNDNQ, היום שלד בפשיטת רגל) שאושרה ב-2010, ה-Ipilimumab של בריסטול מאייר למלנומה שאושר ב-2011. באוקטובר 2015 אישר ה-FDA תרופה בשם ... המאמר מספר על התרופות, אז בתהליכי בדיקות, שהזכרנו קודם ואת חברות הענק שמריצות אותן, BMY, אמג'ן ו-MRK, אבל מתמקד בחמש חברות קטנות שגם הן פיתחו אז תרופות בתחום, DNDN ,GALE ,PPHM ,NLNK ו-INO. "הטיפול האימונותרפי אינו נחלתן של חברות הענק", נכתב, ...
02/10/16 03:40 PMFDA shuts down CTI Bio's pacritinib clinical trials; shares down 46% premarket - Seeking Alpha - FDA shuts down CTI Bio's pacritinib clinical trials; shares down 46% premarketSeeking AlphaAfter reviewing interim overall survival data in CTI BioPharma's (NASDAQ:CTIC) PERSIST-2 clinical trial assessing lead product candidate pacritinib, the FDA has informed the company that its Investigational New Drug (IND) application has been placed on ...and more »
01/19/16 03:03 PMAre MannKind's Lenders Calling The Shots? - Seeking Alpha - Seeking AlphaAre MannKind's Lenders Calling The Shots?Seeking AlphaRight now, we believe the company's debtholders have the majority of the leverage as to which direction the company moves in next, and we will be looking to Deerfield and others who have control over MNKD's debt as to see what the next step for the ...and more »
05/06/15 07:08 AMMy Favorite Under $5 Biotech Could Soar 150% or More -
03/12/15 10:39 PMThe First Rule of Short Selling Is: Don’t Talk About Short Selling -
02/20/15 01:06 PMDendreon’s Enhanced $445 Million Sale to Valeant Approved -
02/10/15 04:51 PMValeant to buy bankrupt vaccine maker Dendreon -
02/05/15 12:19 PMDendreon’s Price Jumps 35% Before Bankruptcy Auction Even Starts -
02/05/15 09:35 AMValeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) - [at noodls] - Bankruptcy Court formally approved Valeant's role as a stalking horse bidder LAVAL, Quebec, Feb. 5, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced ...
01/30/15 05:01 AMDendreon's Asset Rummage Sale Completes the Circle of Life -
01/29/15 10:01 PMValeant to buy Dendreon's prostate cancer vaccine Provenge -
01/29/15 08:29 PMValeant to buy worldwide rights to Dendreon's Provenge -
01/29/15 08:01 PMValeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) - [at noodls] - LAVAL, Quebec, Jan. 29, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into a "stalking horse" asset purchase agreement ...
12/29/14 03:40 PMDendreon heads to auction without initial bidder -
11/11/14 12:43 PMClarification: Dendreon-Chapter 11 Filing story -
11/10/14 01:11 PMDendreon's Dead Enders Still Blaming Everyone But Themselves -
11/10/14 12:31 PMDendreon files for Ch. 11 bankruptcy protection -
11/10/14 11:42 AMUPDATE 2-Dendreon files for bankruptcy as cancer vaccine disappoints -
11/10/14 07:15 AMThe Shame and Lessons of a Dendreon Bankruptcy -
11/10/14 05:54 AMDendreon files for Ch 11 bankruptcy reorganization -
11/10/14 01:22 AMDendreon files for Chapter 11 bankruptcy -
08/12/14 11:54 AMIs an Impending Implosion of Dendreon Avoidable? -
01/26/14 11:18 PMApple And Others Should Issue Debt Now -

Social

About Dendreon

Dendreon logoDendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company's product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company's product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: DNDN
  • CUSIP: 24823Q10
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $N/A
  • 200 Day Moving Average: $N/A
  • P/E Ratio: N/A
  • P/E Growth: N/A
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $-0.730 EPS
  • Next Year EPS Consensus Estimate: $-0.400 EPS
Additional Links:
Dendreon (NASDAQ:DNDN) Chart for Saturday, July, 23, 2016